Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.

Inclusion Criteria: * Are ≥ 18 years of age at the index date * Have a confirmed cancer diagnosis * Received one of the following treatments: * Intravenous (IV) nivolumab * Subcutaneous (SC) nivolumab + hyaluronidase Exclusion Criteria: * Currently receiving a clinical trial therapy at index * Currently receiving treatment for another active concurrent primary cancer diagnosis * Received IV nivolumab or SC nivolumab + hyaluronidase off-label